Cartesian Therapeutics, Inc. (RNAC) stock
RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.08−0.27 (-4.25%)
Close on Nov 16, 2026Market cap $183.95MP/E –Yield –
Cartesian Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Cartesian Therapeutics's total assets was $318.63M at Jun 30, 2026. For fiscal 2025 it was $296.41M, down 31.9% from the year before. Over ten years it grew 21.3% a year on average. The highest annual figure on record is $435.02M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $296.41M | -31.9% |
| FY2024 | Dec 31, 2024 | $435.02M | +42.6% |
| FY2023 | Dec 31, 2023 | $305.05M | +83.9% |
| FY2022 | Dec 31, 2022 | $165.89M | +3.8% |
| FY2021 | Dec 31, 2021 | $159.88M | -3.4% |
| FY2020 | Dec 31, 2020 | $165.44M | +66.2% |
| FY2019 | Dec 31, 2019 | $99.57M | +123.8% |
| FY2018 | Dec 31, 2018 | $44.48M | -56.0% |
| FY2017 | Dec 31, 2017 | $101.10M | +13.2% |
| FY2016 | Dec 31, 2016 | $89.30M | +108.5% |
| FY2015 | Dec 31, 2015 | $42.82M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $318.63M | -18.1% |
| Q1 FY2026 | Mar 31, 2026 | $288.39M | -29.5% |
| Q4 FY2025 | Dec 31, 2025 | $296.41M | -31.9% |
| Q3 FY2025 | Sep 30, 2025 | $372.68M | -18.2% |
| Q2 FY2025 | Jun 30, 2025 | $388.89M | +11.8% |
| Q1 FY2025 | Mar 31, 2025 | $409.13M | +25.8% |
| Q4 FY2024 | Dec 31, 2024 | $435.02M | +42.6% |
| Q3 FY2024 | Sep 30, 2024 | $455.32M | +329.4% |
| Q2 FY2024 | Jun 30, 2024 | $347.74M | +149.3% |
| Q1 FY2024 | Mar 31, 2024 | $325.21M | +108.9% |
| Q4 FY2023 | Dec 31, 2023 | $305.05M | +83.9% |
| Q3 FY2023 | Sep 30, 2023 | $106.03M | -40.5% |
| Q2 FY2023 | Jun 30, 2023 | $139.51M | -25.8% |
| Q1 FY2023 | Mar 31, 2023 | $155.69M | +6.9% |
| Q4 FY2022 | Dec 31, 2022 | $165.89M | +3.8% |
| Q3 FY2022 | Sep 30, 2022 | $178.27M | +6.6% |
| Q2 FY2022 | Jun 30, 2022 | $188.07M | +4.2% |
| Q1 FY2022 | Mar 31, 2022 | $145.70M | -17.6% |
| Q4 FY2021 | Dec 31, 2021 | $159.88M | -3.4% |
| Q3 FY2021 | Sep 30, 2021 | $167.16M | -7.6% |
| Q2 FY2021 | Jun 30, 2021 | $180.52M | +140.0% |
| Q1 FY2021 | Mar 31, 2021 | $176.75M | +99.0% |
| Q4 FY2020 | Dec 31, 2020 | $165.44M | +66.2% |
| Q3 FY2020 | Sep 30, 2020 | $181.00M | +357.7% |
| Q2 FY2020 | Jun 30, 2020 | $75.21M | +60.2% |
| Q1 FY2020 | Mar 31, 2020 | $88.80M | +42.1% |
| Q4 FY2019 | Dec 31, 2019 | $99.57M | +123.8% |
| Q3 FY2019 | Sep 30, 2019 | $39.54M | -34.4% |
| Q2 FY2019 | Jun 30, 2019 | $46.95M | -36.1% |
| Q1 FY2019 | Mar 31, 2019 | $62.48M | -30.5% |
| Q4 FY2018 | Dec 31, 2018 | $44.48M | -56.0% |
| Q3 FY2018 | Sep 30, 2018 | $60.32M | -45.0% |
| Q2 FY2018 | Jun 30, 2018 | $73.44M | -37.2% |
| Q1 FY2018 | Mar 31, 2018 | $89.94M | +21.8% |
| Q4 FY2017 | Dec 31, 2017 | $101.10M | +13.2% |
| Q3 FY2017 | Sep 30, 2017 | $109.72M | +27.9% |
| Q2 FY2017 | Jun 30, 2017 | $117.03M | – |
| Q1 FY2017 | Mar 31, 2017 | $73.86M | – |
| Q4 FY2016 | Dec 31, 2016 | $89.30M | – |
| Q3 FY2016 | Sep 30, 2016 | $85.78M | – |
See a number that looks wrong?